Windlas Biotech
Windlas Biotech Performance
Day Range
- Low 352.35
- High 360
52 Week Range
- Low 212
- High 420.9
- Open Price355.05
- Previous Close355.05
- Volume21725
Start SIP in Windlas Biotech
Start SIPWindlas Biotech Investment Rating
-
Master Rating:
-
Windlas Biotech has an operating revenue of Rs. 537.93 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 11% is healthy, ROE of 10% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 24% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 48 which is a POOR score indicating inconsistency in earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 40 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 145 | 141 | 120 | 133 | 120 | 122 |
Operating Expenses Qtr Cr | 128 | 124 | 106 | 117 | 106 | 108 |
Operating Profit Qtr Cr | 17 | 16 | 14 | 16 | 14 | 14 |
Depreciation Qtr Cr | 3 | 4 | 3 | 3 | 3 | 3 |
Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Qtr Cr | 4 | 4 | 4 | 3 | 4 | -1 |
Net Profit Qtr Cr | 12 | 11 | 9 | 12 | 10 | 15 |
Windlas Biotech Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 10
- Bearish Moving Average
- ___
- 6
- 20 Day
- ₹359.32
- 50 Day
- ₹352.41
- 100 Day
- ₹330.5
- 200 Day
- ₹303.25
- 20 Day
- ₹364.79
- 50 Day
- ₹358.45
- 100 Day
- ₹325.04
- 200 Day
- ₹286.62
Windlas Biotech Resistance and Support
Resistance | |
---|---|
First Resistance | ₹360.25 |
Second Resistance | ₹363.95 |
Third Resistance | ₹367.9 |
RSI | 48.04 |
MFI | 56.22 |
MACD Single Line | -1.06 |
MACD | -2.88 |
Support | |
---|---|
First Resistance | ₹352.6 |
Second Resistance | ₹348.65 |
Third Resistance | ₹344.95 |
Windlas Biotech Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 23,976 | 1,391,807 | 58.05 |
Week | 33,690 | 1,892,042 | 56.16 |
1 Month | 59,491 | 2,853,781 | 47.97 |
6 Month | 87,454 | 3,848,842 | 44.01 |
Windlas Biotech Result Highlights
Windlas Biotech Synopsis
NSE-Medical-Ethical Drugs
Windlas Biotech belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 513.08 Cr. and Equity Capital is Rs. 10.46 Cr. for the Year ended 31/03/2023. Windlas Biotech Ltd. is a Public Limited Listed company incorporated on 19/02/2001 and has its registered office in the State of Uttarakhand/Uttaranchal, India. Company’s Corporate Identification Number(CIN) is L74899UR2001PLC033407 and registration number is 033407.Market Cap | 742 |
Sales | 538 |
Shares in Float | 0.77 |
No of funds | 11 |
Yield | 1.12 |
Book Value | 1.85 |
U/D Vol ratio | 1.7 |
LTDebt / Equity | |
Alpha | 0.15 |
Beta | 0.56 |
Windlas Biotech
Owner Name | Jun-23 | Apr-23 | Mar-23 | Feb-23 |
---|---|---|---|---|
Promoters | 62.82% | 62.44% | 62.38% | 61.22% |
Mutual Funds | 10.51% | 10.65% | 10.64% | 11.32% |
Foreign Portfolio Investors | 0.8% | 1.23% | 1.32% | 1.4% |
Financial Institutions/ Banks | 0.04% | 0.04% | 0.04% | 0.04% |
Individual Investors | 22.01% | 22% | 21.98% | 22.18% |
Others | 3.82% | 3.64% | 3.64% | 3.84% |
Windlas Biotech Management
Name | Designation |
---|---|
Mr. Vivek Dhariwal | Chairman & Ind.Director |
Mr. Hitesh Windlass | Managing Director |
Mr. Manoj Kumar Windlass | Joint Managing Director |
Mr. Pawan Kumar Sharma | Executive Director |
Mr. Ashok Kumar Windlass | Whole Time Director |
Mrs. Prachi Jain Windlass | Non Executive Director |
Mr. Srinivasan Venkataraman | Ind. Non-Executive Director |
Mr. Gaurav Gulati | Ind. Non-Executive Director |
Windlas Biotech Forecast
Price Estimates
Windlas Biotech Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-08-08 | Quarterly Results | |
2023-05-05 | Audited Results & Final Dividend | |
2023-02-08 | Quarterly Results | |
2022-11-08 | Quarterly Results | |
2022-08-04 | Quarterly Results |
- Company Name
- CMP
- Chg(%)
- Hindalco Inds.
- 493
- 5.5
- NTPC
- 246
- 3.6
- Hero Motocorp
- 3057
- 2.9
- Dr Reddys Labs
- 5587
- 2.9
- Divis Lab.
- 3765
- 2.7
- Company Name
- CMP
- Chg(%)
- Adani Enterp.
- 2414
- -2.5
- LTIMindtree
- 5210
- -1.0
- HCL Technologies
- 1235
- -0.6
- Tech Mahindra
- 1223
- -0.5
- Power Grid Corpn
- 200
- -0.5
Windlas Biotech FAQs
What is Share Price of Windlas Biotech ?
Windlas Biotech share price is ₹356 As on 30 September, 2023 | 05:52
What is the Market Cap of Windlas Biotech ?
The Market Cap of Windlas Biotech is ₹741.6 Cr As on 30 September, 2023 | 05:52
What is the P/E ratio of Windlas Biotech ?
The P/E ratio of Windlas Biotech is 16.5 As on 30 September, 2023 | 05:52
What is the PB ratio of Windlas Biotech ?
The PB ratio of Windlas Biotech is 1.8 As on 30 September, 2023 | 05:52